ZIM
KRTX

Zacks Investment Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Zacks Investment Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,353
Closed -$374K – 576
2020
Q2 		$374K Buy
+3,353
New +$292K 0.01% 420

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Zacks Investment Management's KRTX Position: Q3 2020 in Review

Zacks Investment Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2020, closing a stake of 3,353 shares — an estimated $374K sold.

Zacks Investment Management first reported a position in KRTX in Q2 2020 and held it in 1 quarter. The position peaked at $374K in Q2 2020. 132 funds tracked by Wall St. Rank hold KRTX as of Q3 2020.

  • Zacks Investment Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Zacks Investment Management sold 3,353 Karuna Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $374K.
  • Zacks Investment Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Zacks Investment Management's Karuna Therapeutics, Inc. Common Stock position peaked at $374K in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Zacks Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.